Drug Combination Details
| General Information of the Combination (ID: C48727) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Chloroquine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
| Experimental
Result(s) |
CQ exhibits a cytotoxic effect on NB4 cells and has a synergistic effect when combined with ATO, which thereby improves the curative effect of ATO on APL. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide. Oncol Lett. 2018 Feb;15(2):2024-2030. | |||
